Assessment of case definitions for identifying acute liver injury in large observational databases

Drug Safety

Volumn 36, Issue 8, 2013, Pages 651-661

  Katz, Aaron J ^a   Ryan, Patrick B ^b,c   Racoosin, Judith A ^c,d   Stang, Paul E ^b,c  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; DATA BASE; FATIGUE; FEMALE; HEPATOBILIARY DISEASE; HISTORY; HUMAN; JAUNDICE; LIVER INJURY; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; PATIENT MONITORING; PATIENT SATISFACTION; PREVALENCE; PRIORITY JOURNAL; TOXIC HEPATITIS;

ADULT; DATABASES, FACTUAL; DIAGNOSTIC TESTS, ROUTINE; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; UNITED STATES;

EID: 84881121722     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0060-8     Document Type: Article

References (29)

1. Fontana RJ. Approaches to the study of drug-induced liver injury. Clin Pharmacol Ther. 2010;88(3):416-9.
2. Meropol SB, Chan KA, Chen Z, et al. Adverse events associated with prolonged antibiotic use. Pharmacoepidemiol Drug Saf. 2008;17(5):523-32.
3. Garcia-Rodriguez LA, Masso-Gonzalez EL, Wallander MA, et al. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf. 2008;17(10):943-52.
4. Garcia Rodriguez LA, Williams R, Derby LE, et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med. 1994;154(3):311-6.
5. Garcia Rodriguez LA, Duque A, Castellsague J, et al. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol. 1999;48(6):847-52.
6. de Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004;58(1):71-80.
7. Clifford GM, Logie J, Farmer RD. No risk of drug-associated liver injury with alpha1-adrenoreceptor blocking agents in men with BPH: results from an observational study using the GPRD. Pharmacoepidemiol Drug Saf. 2005;14(2):75-80.
8. Suissa S, Ernst P, Hudson M, et al. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med. 2004;117(2):87-92.
9. Perez Gutthann S, Garcia Rodriguez LA. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology. 1993;4(6):496-501.
10. McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf. 2006;15(7):444-53.
11. Lee CH, Wang JD, Chen PC. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf. 2010;19(7):708-14.
12. Jinjuvadia K, Kwan W, Fontana RJ. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol. 2007;102(11):2437-43.
13. Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther. 2007;32(5):483-7.
14. Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol. 2003;98(1):175-9.
15. Goettsch WG, Heintjes EM, Kastelein JJ, et al. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Pharmacoepidemiol Drug Saf. 2006;15(7):435-43.
16. Garcia-Rodriguez LA, Gonzalez-Perez A, Stang MR, et al. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf. 2008;17(10):953-61.
17. Enger C, Gately R, Ming EE, et al. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol. 2010;106(11):1594-601.
18. Duh MS, Vekeman F, Korves C, et al. Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications. Pain Med. 2010;11(11):1718-25.
19. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006;97(8A):61C-8C.
20. Chan KA, Truman A, Gurwitz JH, et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med. 2003;163(6):728-34.
21. Carson JL, Strom BL, Duff A, et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med. 1993;119(7 Pt 1):576-83.
22. Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153(9):600-6.
23. Stang PE, Ryan PB, Dusetzina SB, et al. Health outcomes of interest in observational data: issues in identifying definitions in the literature. Health Outcomes Res Med. 2012;3(1):e37-44.
24. Food and Drug Administration. Guidance for industry on drug-induced liver injury: premarketing clinical evaluation. Silver Spring: US Department of Health and Human Services; 2009. http://www.fda.gov/downloads/Drugs/./Guidances/ UCM174090.pdf (Accessed 26 June 2011).
25. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924-34, 1934.e1-4.
26. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40(Suppl. 1):S5-10.
27. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ. 2009;58(3):1-27.
28. Cohen SM, Ahn J. Review article: the diagnosis and management of alcoholic hepatitis. Aliment Pharmacol Ther. 2009;30(1):3-13.
29. Ozer JS, Chetty R, Kenna G, et al. Recommendations to qualify biomarker candidates of drug-induced liver injury. Biomark Med. 2010;4(3):475-83.